BioSpace News Archive

Veristat, a scientific-minded global clinical research organization, announced the expansion and strengthening of its service capabilities by acquiring SFL.

TLC BioSciences, a clinical-stage specialty pharmaceutical company developing novel nanomedicines to target areas of unmet medical need, announced that detailed results of its TLC599 Phase 2 clinical trial in patients with osteoarthritis of the knee have been published in the peer-reviewed journal Arthritis Research & Therapy.

Orbit Discovery, a ground-breaking peptide discovery company is pleased to announce the commencement of a partnership with WuXi AppTec, a leading global provider of R&D and manufacturing services that enable the global pharmaceutical and healthcare industry.

Elixirgen Therapeutics, Inc. announced that it has entered into an exclusive three-year research collaboration agreement with Taisho Pharmaceutical Co., Ltd.

PathMaker Neurosystems Inc. announced initiation of its U.S. multi-center clinical trial to evaluate MyoRegulator® for the non-invasive treatment of post-stroke upper-limb spasticity.

Evelo Biosciences, Inc. announced that it will host a virtual event titled, “The Future: A no regrets treatment for all stages of psoriasis and broader inflammatory disease.” The event will be held virtually on Friday, March 11, 2022, beginning at 8:00 a.m. ET.

Kinnate Biopharma Inc. announced the presentation of findings from a collaborative study with Tempus investigating the prevalence of Class II and Class III alterations among patients with BRAF-mutated solid tumors.

Dexcom, Inc. is pleased to announce that effective March 14 2022, the Ontario government will provide coverage for the Dexcom G6 CGM System through Ontario’s Assistive Devices Program for people in the province living with type 1 diabetes who are over 2 years of age and meet coverage criteria.

Spectrum Pharmaceuticals, a biopharmaceutical company focused on novel and targeted oncology therapies, announced the presentation of safety and efficacy results from Cohort 4 of the ZENITH20 clinical trial.

Acer Therapeutics Inc. (Nasdaq: ACER), today announced that it has entered into convertible note and loan financing facilities for up to $48.5 million with affiliates of Marathon Asset Management L.P. (Marathon) and SWK Holdings Corporation (Nasdaq: SWKH), subject to certain conditions.